TOCILIZUMAB — all Canadian products
15 DINs
15 marketed/approved
0 in shortage
Every Health Canada Drug Identification Number whose active ingredient is TOCILIZUMAB, with holder, form, strength and current status, compared weekly against the Drug Product Database.
| DIN | Product | Company | Form | Route | Strength | Status | Shortage |
|---|---|---|---|---|---|---|---|
| 02350092 | ACTEMRA | HOFFMANN-LA ROCHE LIMITED | Solution | Intravenous | TOCILIZUMAB 80 MG | Marketed | |
| 02350106 | ACTEMRA | HOFFMANN-LA ROCHE LIMITED | Solution | Intravenous | TOCILIZUMAB 200 MG | Marketed | |
| 02350114 | ACTEMRA | HOFFMANN-LA ROCHE LIMITED | Solution | Intravenous | TOCILIZUMAB 400 MG | Marketed | |
| 02424770 | ACTEMRA | HOFFMANN-LA ROCHE LIMITED | Solution | Subcutaneous | TOCILIZUMAB 162 MG | Marketed | |
| 02483327 | ACTEMRA | HOFFMANN-LA ROCHE LIMITED | Solution | Subcutaneous | TOCILIZUMAB 162 MG | Marketed | |
| 02562049 | AVTOZMA | CELLTRION INC. | Solution | Intravenous | TOCILIZUMAB 400 MG | Marketed | |
| 02562022 | AVTOZMA | CELLTRION INC. | Solution | Intravenous | TOCILIZUMAB 80 MG | Marketed | |
| 02562030 | AVTOZMA | CELLTRION INC. | Solution | Intravenous | TOCILIZUMAB 200 MG | Marketed | |
| 02562057 | AVTOZMA | CELLTRION INC. | Solution | Subcutaneous | TOCILIZUMAB 162 MG | Marketed | |
| 02562065 | AVTOZMA | CELLTRION INC. | Solution | Subcutaneous | TOCILIZUMAB 162 MG | Marketed | |
| 02552450 | TYENNE | FRESENIUS KABI CANADA LTD | Solution | Intravenous | TOCILIZUMAB 80 MG | Marketed | |
| 02552469 | TYENNE | FRESENIUS KABI CANADA LTD | Solution | Intravenous | TOCILIZUMAB 200 MG | Marketed | |
| 02552477 | TYENNE | FRESENIUS KABI CANADA LTD | Solution | Intravenous | TOCILIZUMAB 400 MG | Marketed | |
| 02552485 | TYENNE | FRESENIUS KABI CANADA LTD | Solution | Subcutaneous | TOCILIZUMAB 162 MG | Marketed | |
| 02552493 | TYENNE | FRESENIUS KABI CANADA LTD | Solution | Subcutaneous | TOCILIZUMAB 162 MG | Marketed |
Browse other molecules: